TY - JOUR
T1 - Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease
AU - Genkyst Study Group
AU - the HALT Progression of Polycystic Kidney Disease Group
AU - the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
AU - Cornec-Le Gall, Emilie
AU - Olson, Rory J.
AU - Besse, Whitney
AU - Heyer, Christina M.
AU - Gainullin, Vladimir G.
AU - Smith, Jessica M.
AU - Audrézet, Marie Pierre
AU - Hopp, Katharina
AU - Porath, Binu
AU - Shi, Beili
AU - Baheti, Saurabh
AU - Senum, Sarah R.
AU - Arroyo, Jennifer
AU - Madsen, Charles D.
AU - Férec, Claude
AU - Joly, Dominique
AU - Jouret, François
AU - Fikri-Benbrahim, Oussamah
AU - Charasse, Christophe
AU - Coulibaly, Jean Marie
AU - Yu, Alan S.
AU - Khalili, Korosh
AU - Pei, York
AU - Somlo, Stefan
AU - Le Meur, Yannick
AU - Torres, Vicente E.
AU - Harris, Peter C.
N1 - Funding Information:
We thank the families and coordinators for involvement in the study, and Dr. Cornet (Verviers Hospital, Belgium) and Andrew Metzger and Marie Edwards (Mayo Clinic) for their assistance. The study was supported by NIDDK grant DK058816 (P.C.H.), the Mayo Translational PKD Center ( DK090728 ; V.E.T.), an American Society of Nephrology (ASN) Foundation Kidney Research Fellowship (E.C.-L.G.), the Fulbright Association and the Foundation Monaham (E.C.-L.G.), a PKD Foundation fellowship (W.B.), an American Heart Association postdoctoral fellowship (B.P.), an ASN Ben J. Lipps Fellowship (K.H.), NIDDK Predoctoral Studentships ( F31 ; R.J.O. and J.A.), Mayo Graduate School (R.J.O. and J.A.), the Zell Family Foundation , Robert M. and Billie Kelley Pirnie , and the Belgian Fonds National de la Recherche Scientifique (F.J.). The CRISP and HALT-PKD studies were supported by NIDDK cooperative agreements ( DK056943 , DK056956 , DK056957 , DK056961 , DK062410 , DK062408 , DK062402 , DK082230 , DK062411 , and DK062401 ), National Center for Research Resources General Clinical Research Centers , and National Center for Advancing Translational Sciences Clinical and Translational Science Awards . The Genkyst cohort was supported by National Plans for Clinical Research , Groupement Interregional de Recherche Clinique et d’Innovation (GIRCI Grand Ouest) , and the French Society of Nephrology . The Yale Center for Mendelian Genomics ( UM1 HG006504 ) is funded by the National Human Genome Research Institute . Funds were also provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) program and by the Yale O’Brien Kidney Center ( P30 DK079310 ). Acknowledgment to other HALT PKD, CRISP, and Genkyst investigators is given in the Supplemental Data .
Funding Information:
We thank the families and coordinators for involvement in the study, and Dr. Cornet (Verviers Hospital, Belgium) and Andrew Metzger and Marie Edwards (Mayo Clinic) for their assistance. The study was supported by NIDDK grant DK058816 (P.C.H.), the Mayo Translational PKD Center (DK090728; V.E.T.), an American Society of Nephrology (ASN) Foundation Kidney Research Fellowship (E.C.-L.G.), the Fulbright Association and the Foundation Monaham (E.C.-L.G.), a PKD Foundation fellowship (W.B.), an American Heart Association postdoctoral fellowship (B.P.), an ASN Ben J. Lipps Fellowship (K.H.), NIDDK Predoctoral Studentships (F31; R.J.O. and J.A.), Mayo Graduate School (R.J.O. and J.A.), the Zell Family Foundation, Robert M. and Billie Kelley Pirnie, and the Belgian Fonds National de la Recherche Scientifique (F.J.). The CRISP and HALT-PKD studies were supported by NIDDK cooperative agreements (DK056943, DK056956, DK056957, DK056961, DK062410, DK062408, DK062402, DK082230, DK062411, and DK062401), National Center for Research Resources General Clinical Research Centers, and National Center for Advancing Translational Sciences Clinical and Translational Science Awards. The Genkyst cohort was supported by National Plans for Clinical Research, Groupement Interregional de Recherche Clinique et d'Innovation (GIRCI Grand Ouest), and the French Society of Nephrology. The Yale Center for Mendelian Genomics (UM1 HG006504) is funded by the National Human Genome Research Institute. Funds were also provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) program and by the Yale O'Brien Kidney Center (P30 DK079310). Acknowledgment to other HALT PKD, CRISP, and Genkyst investigators is given in the Supplemental Data.
Publisher Copyright:
© 2018 American Society of Human Genetics
PY - 2018/5/3
Y1 - 2018/5/3
N2 - Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by the progressive development of kidney cysts, often resulting in end-stage renal disease (ESRD). This disorder is genetically heterogeneous with ∼7% of families genetically unresolved. We performed whole-exome sequencing (WES) in two multiplex ADPKD-like pedigrees, and we analyzed a further 591 genetically unresolved, phenotypically similar families by targeted next-generation sequencing of 65 candidate genes. WES identified a DNAJB11 missense variant (p.Pro54Arg) in two family members presenting with non-enlarged polycystic kidneys and a frameshifting change (c.166_167insTT) in a second family with small renal and liver cysts. DNAJB11 is a co-factor of BiP, a key chaperone in the endoplasmic reticulum controlling folding, trafficking, and degradation of secreted and membrane proteins. Five additional multigenerational families carrying DNAJB11 mutations were identified by the targeted analysis. The clinical phenotype was consistent in the 23 affected members, with non-enlarged cystic kidneys that often evolved to kidney atrophy; 7 subjects reached ESRD from 59 to 89 years. The lack of kidney enlargement, histologically evident interstitial fibrosis in non-cystic parenchyma, and recurring episodes of gout (one family) suggested partial phenotypic overlap with autosomal-dominant tubulointerstitial diseases (ADTKD). Characterization of DNAJB11-null cells and kidney samples from affected individuals revealed a pathogenesis associated with maturation and trafficking defects involving the ADPKD protein, PC1, and ADTKD proteins, such as UMOD. DNAJB11-associated disease is a phenotypic hybrid of ADPKD and ADTKD, characterized by normal-sized cystic kidneys and progressive interstitial fibrosis resulting in late-onset ESRD.
AB - Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by the progressive development of kidney cysts, often resulting in end-stage renal disease (ESRD). This disorder is genetically heterogeneous with ∼7% of families genetically unresolved. We performed whole-exome sequencing (WES) in two multiplex ADPKD-like pedigrees, and we analyzed a further 591 genetically unresolved, phenotypically similar families by targeted next-generation sequencing of 65 candidate genes. WES identified a DNAJB11 missense variant (p.Pro54Arg) in two family members presenting with non-enlarged polycystic kidneys and a frameshifting change (c.166_167insTT) in a second family with small renal and liver cysts. DNAJB11 is a co-factor of BiP, a key chaperone in the endoplasmic reticulum controlling folding, trafficking, and degradation of secreted and membrane proteins. Five additional multigenerational families carrying DNAJB11 mutations were identified by the targeted analysis. The clinical phenotype was consistent in the 23 affected members, with non-enlarged cystic kidneys that often evolved to kidney atrophy; 7 subjects reached ESRD from 59 to 89 years. The lack of kidney enlargement, histologically evident interstitial fibrosis in non-cystic parenchyma, and recurring episodes of gout (one family) suggested partial phenotypic overlap with autosomal-dominant tubulointerstitial diseases (ADTKD). Characterization of DNAJB11-null cells and kidney samples from affected individuals revealed a pathogenesis associated with maturation and trafficking defects involving the ADPKD protein, PC1, and ADTKD proteins, such as UMOD. DNAJB11-associated disease is a phenotypic hybrid of ADPKD and ADTKD, characterized by normal-sized cystic kidneys and progressive interstitial fibrosis resulting in late-onset ESRD.
KW - ADPKD
KW - ADPLD
KW - ADTKD
KW - DNAJB11
KW - pathogenic variants
KW - renal cystic disease
UR - http://www.scopus.com/inward/record.url?scp=85046156677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046156677&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2018.03.013
DO - 10.1016/j.ajhg.2018.03.013
M3 - Article
C2 - 29706351
AN - SCOPUS:85046156677
SN - 0002-9297
VL - 102
SP - 832
EP - 844
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 5
ER -